Isomorphic Labs trains computational models to predict molecular structures and interactions at experimental accuracy

Overview Debates Related claims Topics

Traditional drug development relies on empirical trial-and-error screening processes rather than predictive computational modeling

Isomorphic Labs partners with biopharmaceutical companies to apply its artificial intelligence drug design engine to partner drug targets

Isomorphic Labs was created with the stated mission of solving all human disease

AlphaFold's demonstration of protein structure prediction served as the proof of concept that led to the founding of Isomorphic Labs

Organoids and organ-on-a-chip technologies create synthetic microenvironments of human tissues to simulate human organ responses

Preclinical toxicity studies conducted in rats are approximately 30 percent predictive of clinical toxicity in humans

Isomorphic Labs utilizes automated laboratories to generate experimental data to power computational models

Automated wet laboratories and robotic platforms remain constrained by physical reaction rates and cell culturing times

Traditional pharmaceutical research typically treats each drug program as a bespoke project, limiting transferable learnings to subsequent programs

Determining protein structures through X-ray crystallography traditionally requires months or years of laboratory experiments

In-vitro laboratory endpoints can be combined with computational predictive models and synthetic human tissues to assess clinical toxicity

Data repositories from historical pharmaceutical research often reflect biased sampling that limits machine learning model generalization

The RAS protein family has been studied as a driver of cancer in biological research since the early 1990s

Isomorphic Labs relies on physical laboratory experiments primarily for hypothesis validation rather than iterative discovery

AlphaGenome increased genomic prediction resolution from Enformer's 128 base pairs down to single base-pair resolution

Researchers at the Francis Crick Institute experimentally validated that a non-coding variant regulates a target gene situated 290,000 base pairs away

AlphaGenome Atlas precomputed variant effect predictions across all 9 billion possible single-nucleotide mutations in the human genome

In 2025, Google DeepMind unveiled AlphaGenome to predict the function of non-coding DNA across whole tissues

AlphaGenome 2 allows external researchers to input custom cell-type data to generate variant effect predictions without fine-tuning the model

AlphaGenome 2 evaluates variant impacts at the individual cell-type level rather than aggregate bulk tissue measurements